Skip to main content
SpringerLink
Log in

Flavocoxid, an anti-inflammatory agent of botanical origin, does not affect coagulation or interact with anticoagulation therapies

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Flavocoxid, a botanical, anti-inflammatory agent, nonspecifically inhibits the peroxidase activity of cyclooxygenase (COX-1 and COX-2) enzymes and 5-lipooxygenase (5-LOX). Due to the concomitant use of aspirin or warfarin in many osteoarthritis (OA) patients with increased cardiovascular risk, we felt it necessary to assess the anticoagulation properties of flavocoxid.

Methods

Three different studies were used: 1) a mouse model to assess effects on bleeding times when combined with aspirin; 2) the effect on platelet function as evaluated by platelet aggregation and bleed times in healthy human subjects; and 3) the effect on international normalized ratio in previously warfarinized patients with OA.

Results

Flavocoxid at a human equivalent dose (HED) of 569 mg (within the standard human dosing range of 500 mg) produced no significant increases in bleeding time in mice. There was also no inhibition or synergistic increase in bleed times when flavocoxid was combined with aspirin (370 mg HED). Flavocoxid did not significantly inhibit thromboxane production or platelet aggregation, and did not increase bleeding times in healthy volunteers. Finally, flavocoxid did not inhibit or potentiate the anticoagulant effect of warfarin.

Conclusion

These results suggest that flavocoxid does not affect the primary or extrinsic pathways of secondary hemostasis and, by not inhibiting the anticoagulation effects of aspirin, may have utility in cardiovascular patients with OA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Burnett BP, Levy R, Cole BJ. Metabolic mechanisms in the pathogenesis of osteoarthritis. A review. J Knee Surg. 2006;19:191–197.

    PubMed  Google Scholar 

  2. Paulus HE. FDA arthritis advisory committee meeting: serious gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs, etc. Arthritis Rheum. 1988;31:1450–1451.

    Article  Google Scholar 

  3. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769–772.

    Article  PubMed  CAS  Google Scholar 

  4. Cronberg S, Wallmark E, Soderberg I. Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol. 1984;33:155–159.

    PubMed  CAS  Google Scholar 

  5. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975;72:3073–3076.

    Article  PubMed  CAS  Google Scholar 

  6. Van Hecken A, Schwartz JI, Depré M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen. J Clin Pharmacol. 2000;40:1109–1120.

    PubMed  Google Scholar 

  7. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206–1218.

    PubMed  CAS  Google Scholar 

  8. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809–1817.

    Article  PubMed  CAS  Google Scholar 

  9. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005;45:1295–1301.

    Article  PubMed  CAS  Google Scholar 

  10. Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation. 2003;108:1191–1195.

    Article  PubMed  CAS  Google Scholar 

  11. Greenberg HE, Gottesdiener K, Huntington M, et al. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol. 2000;40:1509–1515.

    PubMed  CAS  Google Scholar 

  12. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 2000;40:124–132.

    Article  PubMed  CAS  Google Scholar 

  13. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095–1106.

    Article  PubMed  CAS  Google Scholar 

  14. Chan TY. Prolongation of prothrombin time with the use of indomethacin and warfarin. Br J Clin Pract. 1997;51:177–178.

    PubMed  CAS  Google Scholar 

  15. Rhodes RS, Rhodes PJ, Klein C, Sintek CD. A warfarin-piroxicam drug interaction. Drug Intell Clin Pharm. 1985;19:556–558.

    PubMed  CAS  Google Scholar 

  16. Schwartz JI, Bugianesi KJ, Ebel DL, et al. The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin. Clin Pharmacol Ther. 2000;68:626–636.

    Article  PubMed  CAS  Google Scholar 

  17. Karim A, Tolbert D, Piergies A, et al. Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects. J Clin Pharmacol. 2000;40:655–663.

    Article  PubMed  CAS  Google Scholar 

  18. Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy. 2004;24:1668–1674.

    Article  PubMed  CAS  Google Scholar 

  19. Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med. 2005;165:189–192.

    Article  PubMed  CAS  Google Scholar 

  20. Chan TY. Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance. Ann Pharmacother. 1995;29:1274–1283.

    PubMed  CAS  Google Scholar 

  21. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993;153:1665–1670.

    Article  PubMed  CAS  Google Scholar 

  22. FDA web site. FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). April 7, 2005, Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108427.htm. Accessed: May 26, 2010.

  23. Altavilla D, Squadrito F, Bitto A, et al. Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin stimulated macrophages. Br J Pharmacol. 2009;157:1410–1418.

    Article  PubMed  CAS  Google Scholar 

  24. Jia Q. Generating and screening a natural product library for cyclooxygenase and lipoxygenase dual inhibitors. Studies in Natural Product Chemistry. 2003;29:P643–P718.

    Article  Google Scholar 

  25. Butler KD, Maguire ED, Smith JR, Turnbull AA, Wallis RB, White AM. Prolongation of rat tail bleeding time caused by oral doses of a thromboxane synthetase inhibitor which have little effect on platelet aggregation. Thromb Haemost. 1982;47:46–49.

    PubMed  CAS  Google Scholar 

  26. Weiss HJ. Platelet physiology and abnormalities of platelet function (first of two parts). N Engl J Med. 1975;293:531–541.

    PubMed  CAS  Google Scholar 

  27. Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2003;62:501–509.

    Article  PubMed  CAS  Google Scholar 

  28. Levy R, Saikovsky R, Shmidt E, Khokhlov A, Burnett BP. Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study. Nutr Res. 2009;29:298–304.

    Article  PubMed  CAS  Google Scholar 

  29. Pillai L, Burnett BP, Levy RM. GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin. Curr Med Res Opin. 2010;26:1055–1063.

    Article  PubMed  CAS  Google Scholar 

  30. Cooper R, Morre DJ, Morre DM. Medicinal benefits of green tea: Part I. Review of noncancer health benefits. J Altern Complement Med. 2005;11:521–528.

    Article  PubMed  Google Scholar 

  31. Shao ZH, Vanden Hoek TL, Qin Y, et al. Baicalein attenuates oxidant stress in cardiomyocytes. Am J Physiol Heart Circ Physiol. 2002;282:H999–H1006.

    PubMed  CAS  Google Scholar 

  32. Institute of Laboratory Animal Research, Commission on Life Sciences, National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.

    Google Scholar 

  33. Burnett BP, Jia Q, Zhao Y, Levy RM. A medicinal extract of Scutellaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce inflammation. J Med Food. 2007;10:442–451.

    Article  PubMed  CAS  Google Scholar 

  34. Graff J, Skarke C, Klinkhardt U, et al. Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers. J Thromb Haemost. 2007;5:2376–2385.

    Article  PubMed  CAS  Google Scholar 

  35. Mielke CH, Jr., Kaneshiro MM, Maher IA, Weiner JM, Rapaport SI. The standardized normal ivy bleeding time and its prolongation by aspirin. Blood. 1969;34:204–215.

    PubMed  Google Scholar 

  36. Escolar G, Cases A, Vinas M, et al. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): influence of hematocrit elevation. Haematologica. 1999;84:614–619.

    PubMed  CAS  Google Scholar 

  37. Guerrero JA, Navarro-Nunez L, Lozano ML, et al. Flavonoids inhibit the platelet TxA(2) signalling pathway and antagonize TxA(2) receptors (TP) in platelets and smooth muscle cells. Br J Clin Pharmacol. 2007;64:133–144.

    Article  PubMed  CAS  Google Scholar 

  38. Burnett BP, Pillai L, Levy RM: editors. Flavocoxid, a natural novel flavonoid-based anti-inflammatory with a broad mechanism of action provides safe and effective inflammatory management of disease. Phoenix, AZ: Society for Biomolecular Science; 2010.

    Google Scholar 

  39. Son DJ, Cho MR, Jin YR, et al. Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway. Prostaglandins Leukot Essent Fatty Acids. 2004;71:25–31.

    Article  PubMed  CAS  Google Scholar 

  40. Heptinstall S, May J, Fox S, Kwik-Uribe C, Zhao L. Cocoa flavanols and platelet and leukocyte function: recent in vitro and ex vivo studies in healthy adults. J Cardiovasc Pharmacol. 2006;47(suppl. 2):S197–205.

    Article  PubMed  CAS  Google Scholar 

  41. Pignatelli P, Pulcinelli FM, Celestini A, et al. The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide. Am J Clin Nutr. 2000;72:1150–1155.

    PubMed  CAS  Google Scholar 

  42. Liu JJ, Huang TS, Cheng WF, Lu FJ. Baicalein and baicalin are potent inhibitors of angiogenesis: Inhibition of endothelial cell proliferation, migration and differentiation. Int J Cancer. 2003;106:559–565.

    Article  PubMed  CAS  Google Scholar 

  43. Navarro-Nunez L, Castillo J, Lozano ML, et al. Thromboxane A2 receptor antagonism by flavonoids: structure-activity relationships. J Agric Food Chem. 2009;57:1589–1594.

    Article  PubMed  CAS  Google Scholar 

  44. Selg E, Buccellati C, Andersson M, et al. Antagonism of thromboxane receptors by diclofenac and lumiracoxib. Br J Pharmacol. 2007;152:1185–1195.

    Article  PubMed  CAS  Google Scholar 

  45. Burnett BP, Silva S, Mesches MH, Jia Q. Safety Evaluation of a combination, defined extract of Scutellaria baicalensis and Acacia catechu. J Food Biochem. 2007;31:797–825.

    Article  CAS  Google Scholar 

  46. Morgan SL, Baggott JE, Moreland L, Desomond R, Kendrach A. The safety of flavocoxid, a medical food, in the dietary management of knee osteoarthritis. J Medicinal Foods. 2009;12:1143–1148.

    Article  CAS  Google Scholar 

  47. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther. 2005;77:1–16.

    Article  PubMed  CAS  Google Scholar 

  48. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353:717–719.

    Article  PubMed  CAS  Google Scholar 

  49. Levy RM, Pillai L, Burnett BP. Nutritional benefits of flavocoxid in patients with osteoarthritis: efficacy and safety. Nutr Diet Supple. 2010;2:1–12.

    Google Scholar 

  50. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000;38:225–242.

    Article  PubMed  CAS  Google Scholar 

  51. Malhi H, Atac B, Daly AK, Gupta S. Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. Postgrad Med J. 2004;80:107–109.

    Article  PubMed  CAS  Google Scholar 

  52. Gabb GM. Fatal outcome of interaction between warfarin and a non-steroidal anti-inflammatory drug. Med J Aust. 1996;164:700–701.

    PubMed  CAS  Google Scholar 

  53. Geleijnse JM, Launer LJ, Hofman A, Pols HA, Witteman JC. Tea flavonoids may protect against atherosclerosis: the Rotterdam Study. Arch Intern Med. 1999;159:2170–2174.

    Article  PubMed  CAS  Google Scholar 

  54. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet. 1993;342:1007–1011.

    Article  PubMed  CAS  Google Scholar 

  55. Limbrel web site. Limbrel Post Marketing Surveillance. Primus Pharmaceuticals; 2010. Available at: www.limbrel.com/downloads/post_mkt_surv.pdf. Accessed December 1, 2009.

Download references

Author information

Authors and Affiliations

  1. Primus Pharmaceuticals, Inc., 4725 N. Scottsdale Rd, Suite 200, Scottsdale, AZ, 85251, USA

    Lakshmi Pillai, Robert M. Levy & Bruce P. Burnett

  2. Unigen Pharmaceuticals, Inc., 2660 Willamette Drive, NE, Lacey, WA, 98516, USA

    Mesfin Yimam, Yuan Zhao & Qi Jia

Authors
  1. Lakshmi Pillai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert M. Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mesfin Yimam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qi Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bruce P. Burnett
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruce P. Burnett.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pillai, L., Levy, R.M., Yimam, M. et al. Flavocoxid, an anti-inflammatory agent of botanical origin, does not affect coagulation or interact with anticoagulation therapies. Adv Therapy 27, 400–411 (2010). https://doi.org/10.1007/s12325-010-0040-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-010-0040-7

Keywords

Search

Navigation